Moonlake Immunotherapeutics (MLTX)

Moonlake Immunotherapeutics stock is traded at $10.80, with a volume of 1,337,583. It is down -6.57% in the last 24 hours and down -1.37% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.